• Product NameRecombinant Human Transforming Growth Factor - beta 2
• Host SpeciesMouse myeloma cell line, NS0
• Purification> 97 % by SDS-PAGE analyses.
• Biological ActivityMeasured by its ability to inhibit the IL-4-dependent proliferation of HT-2 mouse T cells. The ED50 for this effect is 0.025-0.25 ng/ml.
• EndotoxinLess than 0.1 EU/ug of rHuTGF-β2 as determined by LAL method.
• Calculated MW Apparent molecular mass of 24 kDa in SDS-PAGE under non-reducing conditions, 12 kDa under reducing conditions, a disulfide-linked homodimer of two 112 amino acid glycosylated polypeptide chains.
• Target Sequence Ala303-Ser414; Accession # P61812
• Formulation Lyophilized from 0.2 μm filtered concentrated solution in 35 % Acetonitrile and 0.1 % TFA.
• Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.- 12 months from date of receipt, -20 to -70 ˚C as supplied.- 1 month, 2 to 8 ˚C under sterile conditions after reconstitution.- 3 months, -20 to -70 ˚C under sterile conditions after reconstitution.

TGF-β2 is a pleiotropic cytokine that regulates immune function, cellular proliferation, and epithelial-mesenchymal transition. It shows cross-species activity in the development of cardiac, lung, craniofacial, limb, eye, ear, and urogenital systems. Latent TGF-β is activated by proteolytic cleavage of the mature cytokine from the latency-associated peptide. TGF-β2 signaling involves the accessory receptor Betaglycan, TGF-β RII, and a type I TGF-β receptor, resulting in the activation of Smad signal transduction.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting